Elanco Animal Health Inc ELAN
We take great care to ensure that the data presented and summarized in this overview for Elanco Animal Health Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELAN
View all-
Dodge & Cox San Francisco, CA83.2MShares$926 Million0.63% of portfolio
-
Primecap Management CO Pasadena, CA51.2MShares$569 Million0.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA48.8MShares$543 Million0.01% of portfolio
-
Black Rock Inc. New York, NY23.3MShares$259 Million0.01% of portfolio
-
Black Creek Investment Management Inc. Toronto, A620.4MShares$227 Million11.79% of portfolio
-
Dimensional Fund Advisors LP Austin, TX17.9MShares$199 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD15.7MShares$175 Million0.12% of portfolio
-
Shapiro Capital Management LLC Atlanta, GA12.4MShares$138 Million5.14% of portfolio
-
Magnetar Financial LLC Evanston, IL12MShares$134 Million4.77% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL11.8MShares$131 Million0.04% of portfolio
Latest Institutional Activity in ELAN
Top Purchases
Top Sells
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Insider Transactions at ELAN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 19
2025
|
Grace Mc Ardle EVP, MANUFACTURING AND QUALITY |
SELL
Payment of exercise price or tax liability
|
Direct |
2,596
-4.46%
|
$28,556
$11.24 P/Share
|
Feb 19
2025
|
Grace Mc Ardle EVP, MANUFACTURING AND QUALITY |
BUY
Grant, award, or other acquisition
|
Direct |
8,025
+12.11%
|
-
|
Feb 19
2025
|
Jeffrey N Simmons PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
195,840
-10.83%
|
$2,154,240
$11.24 P/Share
|
Feb 19
2025
|
Jeffrey N Simmons PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
449,408
+19.9%
|
-
|
Feb 19
2025
|
De Simas Jose Manuel Correia |
SELL
Payment of exercise price or tax liability
|
Direct |
11,808
-15.57%
|
$129,888
$11.24 P/Share
|
Feb 19
2025
|
De Simas Jose Manuel Correia |
BUY
Grant, award, or other acquisition
|
Direct |
26,082
+25.59%
|
-
|
Feb 19
2025
|
Todd S. Young |
SELL
Payment of exercise price or tax liability
|
Direct |
46,045
-22.45%
|
$506,495
$11.24 P/Share
|
Feb 19
2025
|
Todd S. Young |
BUY
Grant, award, or other acquisition
|
Direct |
104,930
+33.84%
|
-
|
Feb 19
2025
|
Ramiro Martin Cabral |
SELL
Payment of exercise price or tax liability
|
Direct |
30,093
-12.68%
|
$331,023
$11.24 P/Share
|
Feb 19
2025
|
Ramiro Martin Cabral |
BUY
Grant, award, or other acquisition
|
Direct |
68,214
+22.33%
|
-
|
Feb 19
2025
|
David S Kinard |
SELL
Payment of exercise price or tax liability
|
Direct |
17,968
-9.36%
|
$197,648
$11.24 P/Share
|
Feb 19
2025
|
David S Kinard |
BUY
Grant, award, or other acquisition
|
Direct |
40,247
+17.34%
|
-
|
Feb 19
2025
|
James M Meer CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,691
-5.16%
|
$29,601
$11.24 P/Share
|
Feb 19
2025
|
James M Meer CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
7,825
+13.05%
|
-
|
Feb 19
2025
|
Shiv O'Neill GC AND CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
2,943
-9.88%
|
$32,373
$11.24 P/Share
|
Feb 19
2025
|
Shiv O'Neill GC AND CORP SEC |
BUY
Grant, award, or other acquisition
|
Direct |
6,019
+16.81%
|
-
|
Feb 19
2025
|
Rajeev A. Modi |
SELL
Payment of exercise price or tax liability
|
Direct |
18,737
-16.53%
|
$206,107
$11.24 P/Share
|
Feb 19
2025
|
Rajeev A. Modi |
BUY
Grant, award, or other acquisition
|
Direct |
42,133
+27.1%
|
-
|
Feb 19
2025
|
Ellen De Brabander |
SELL
Payment of exercise price or tax liability
|
Direct |
69,916
-27.3%
|
$769,076
$11.24 P/Share
|
Feb 19
2025
|
Ellen De Brabander |
BUY
Grant, award, or other acquisition
|
Direct |
141,244
+35.54%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.78M shares |
---|---|
Open market or private purchase | 157K shares |
Bona fide gift | 41K shares |
Payment of exercise price or tax liability | 662K shares |
---|---|
Bona fide gift | 41K shares |